{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-027545","form_type":"8-K","ticker":"LCTX","cik":"0000876343","company_name":"Lineage Cell Therapeutics, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.843801+00:00","generated_at":"2026-06-11T20:57:20.358407+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lineage Q2 net loss narrows to $5.2M; OpRegen phase 2a enrolling, OPC1 IND plan in Q4","bullets":["Net loss narrowed to $5.2M ($0.03/shr) from $6.8M ($0.04/shr) in Q2 2022.","Revenue fell to $3.2M from $4.6M YoY, driven by lower Roche collaboration revenue.","Cash $45.9M; expected to fund operations into Q4 2024.","OpRegen Phase 2a enrolling; FDA meeting response enables OPC1 delivery device IND amendment in Q4.","VAC2 Phase 1 topline: five of eight stable disease; three of eight reached 2-year survival."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-027545","json":"https://secwatch.observer/filing/0001493152-23-027545.json","markdown":"https://secwatch.observer/filing/0001493152-23-027545.md","text":"https://secwatch.observer/filing/0001493152-23-027545.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876343/000149315223027545/0001493152-23-027545-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876343/000149315223027545/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T20:57:20.358407+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1720c2c77f99500e4fe928a2aa4499b8aa03dc92","claim":"Lineage Cell Therapeutics, Inc. reported second quarter ended June 30, 2023 results: revenue $3.2 million.","evidence_excerpt":"revenue is generated primarily from licensing fees, royalties, collaboration revenues, and research grants. Total revenues for the three months ended June 30, 2023 were $3.2 million, a net decrease of $1.4 million as compared to approximately $4.6 million for the same period in 2022. The decrease was primarily driven by less collaboration and licensing","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223027545/0001493152-23-027545-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$3.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}